SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending amidst a broader "SPAC mania," with community discussion centered on its exceptionally low public float and high insider ownership. Traders are actively comparing it to recent explosive movers like AFJK, believing ESHA's tight share structure positions it for significant, rapid gains. This setup is fueling speculative interest and discussions around its potential for sharp upward price action.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending due to the FDA approval of NEREUS, which marks the first new pharmacologic treatment for motion sickness in over four decades and is seen by many as significantly under-modeled by the market. The community is actively discussing its potential for off-label use in addressing GLP-1 induced nausea, positioning it as a major upside driver with billions in market potential and fueling significant speculation about a potential buyout from a larger GL-1 focused pharmaceutical company. This approval, coupled with other pipeline catalysts, signals a significant re-rating opportunity for VNDA as it transitions into a commercial-stage company.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending sharply lower after receiving a Complete Response Letter from the FDA for its relacorilant drug, intended for Cushing's syndrome. The community is actively debating the severe market reaction, with many expressing disappointment and predicting further downside, while others view the significant dip as a potential buying opportunity. This decision casts a shadow on the company's near-term growth strategy and future pipeline utilizing similar mechanisms, prompting discussions around its market valuation relative to existing revenue and competitors.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending amid news of a new manufacturing partnership aimed at boosting production and margins, coupled with persistent community focus on its ongoing FDA 510(k) clearance process for a non-invasive fingerprint drug screening system. Investors are keenly anticipating the potential for significant upside from U.S. market entry, driven by the technology's innovation and the stock's low float, though concerns around potential dilution and extended FDA timelines continue to spark debate.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology ($AFJK) is currently a prime focus for event-driven traders due to its low float and ongoing speculation around potential business combination news, fueling significant volatility. The community is actively discussing its potential for short squeezes and its resemblance to other recent high-flying SPACs in a speculative market.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is gaining significant attention following the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 for Alzheimer's agitation. This expedited regulatory pathway is sparking considerable investor excitement, with the community highly optimistic about the company's expanding central nervous system pipeline and the continued strong commercial performance of its existing therapies.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as a key competitor, Corcept Therapeutics, faced an FDA Complete Response Letter for its Cushing's syndrome treatment, effectively clearing the path for Xeris's rapidly growing Recorlev to capture more market share. The community is buzzing with enthusiasm, emphasizing Xeris's strong gross margins, anticipated profitability, and the multi-blockbuster potential of its XP-8121 pipeline, leading to widespread expectations for a significant re-rating by analysts.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as China extends crucial EV trade-in subsidies into 2026, coinciding with the CEO's upbeat Q4 sales forecast and recent rapid delivery milestones for its ES8 model. The community is sharply divided, with bulls anticipating a significant short squeeze and potential profitability driven by NIO's unique battery swap ecosystem, while others remain skeptical about sustained gains despite these positive developments.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corporation (BULL) is actively trending as investors discuss significant year-end tax loss harvesting contributing to recent price declines. Community sentiment is sharply divided, with optimists highlighting the fintech brokerage's profitability, growing user base, and international expansion as a long-term opportunity, while skeptics warn of persistent dilution and fierce competition.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Blockchain Inc

Riot Platforms is trending due to a new stock offering, sparking community debate about potential dilution and its impact on share value. Many investors are vocalizing concerns, with some labeling it a "share selling scam" and noting the stock's struggle to align with broader cryptocurrency market trends. Amidst this, there's ongoing discussion about the company's potential to secure AI/datacenter contracts to leverage its energy capacity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apimeds Pharmaceuticals says I love my Ducks with new ai Futures Lab Program collaboration with the University of Oregons Lundquist College of Business

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (Apimeds) today announced the expansion of the Apimeds ai Futures Lab program through a new collaboration with the University of Oregons Lundquist...

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.

APUS
Apimeds Pharmaceuticals US Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest APUS News

APUSApimeds Pharmaceuticals US Inc.